is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day One Biopharmaceuticals for its paediatric glioma therapy Ojemda (tovorafenib). Ipsen will make an upfront payment of $111m, of which $71m will be in cash and the rest will be an equity investment. Day One will also be in line to receive up to $350m in milestone-based milestones and ‘double-digit’ royalties on sales.
As part of the agreement, the French pharmaceutical will gain global commercial rights, excluding the US, for Ojemda. Day One will retain global development and the US commercial rights for the therapy. inhibits type II rapidly accelerated fibrosarcoma (RAF) kinases and is being developed to treat paediatric low-grade glioma with BRAF rearrangements.
Low-grade gliomas are a group of slow-growing tumours that can occur in the brain and spinal cord. It is the most common central nervous system tumour type in children and adolescents, accounting for of brain and spinal cord tumours in this population, as per the American Brain Tumor Association. In April, Ojemda received accelerated approval by the US Food and Drug Administration (FDA) to treat patients six months of age and older with relapsed or refractory paediatric low-grade glioma harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation.
The therapy is expected to generate approximately $797m in sales in 2030, as per GlobalData analysis. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form GlobalData is the parent company of Ojemda is being evaluated in patients with low-grade gliomas in a Phase III FIREFLY-2 trial (NCT05566795).
The study will investigate the therapy against standard chemotherapy in approximately 400 patients. The trial’s primary endpoint is the objective response rate based on response assessment in neuro-oncology (RANO) criteria, as determined by an independent review. Another therapy area in which both Ipsen and Day One have individually invested is antibody-drug conjugates (ADCs).
Last month, Day One signed a for its ADC worth up to $1.2bn. Ipsen signed two this year—with in April and Foreseen Biotechnology this month.
Phase I trials investigating both ADCs are expected to start in the coming months. Give your business an edge with our leading industry insights..
